107 related articles for article (PubMed ID: 37844597)
1. Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial.
Grimm MO; Esteban E; Barthélémy P; Schmidinger M; Busch J; Valderrama BP; Charnley N; Schmitz M; Schumacher U; Leucht K; Foller S; Baretton G; Duran I; de Velasco G; Priou F; Maroto P; Albiges L;
Lancet Oncol; 2023 Nov; 24(11):1252-1265. PubMed ID: 37844597
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.
Oaknin A; Moore K; Meyer T; López-Picazo González J; Devriese LA; Amin A; Lao CD; Boni V; Sharfman WH; Park JC; Tahara M; Topalian SL; Magallanes M; Molina Alavez A; Khan TA; Copigneaux C; Lee M; Garnett-Benson C; Wang X; Naumann RW
Lancet Oncol; 2024 May; 25(5):588-602. PubMed ID: 38608691
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
Hellmann MD; Rizvi NA; Goldman JW; Gettinger SN; Borghaei H; Brahmer JR; Ready NE; Gerber DE; Chow LQ; Juergens RA; Shepherd FA; Laurie SA; Geese WJ; Agrawal S; Young TC; Li X; Antonia SJ
Lancet Oncol; 2017 Jan; 18(1):31-41. PubMed ID: 27932067
[TBL] [Abstract][Full Text] [Related]
4. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.
Motzer RJ; Escudier B; McDermott DF; Arén Frontera O; Melichar B; Powles T; Donskov F; Plimack ER; Barthélémy P; Hammers HJ; George S; Grünwald V; Porta C; Neiman V; Ravaud A; Choueiri TK; Rini BI; Salman P; Kollmannsberger CK; Tykodi SS; Grimm MO; Gurney H; Leibowitz-Amit R; Geertsen PF; Amin A; Tomita Y; McHenry MB; Saggi SS; Tannir NM
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32661118
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab + Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma: A Nonrandomized Clinical Trial.
Grimm MO; Schostak M; Grün CB; Loidl W; Pichler M; Zimmermann U; Schmitz-Dräger B; Steiner T; Roghmann F; Niegisch G; Bolenz C; Schmitz M; Baretton G; Leucht K; Schumacher U; Foller S; Zengerling F; Meran J;
JAMA Oncol; 2024 May; ():. PubMed ID: 38722641
[TBL] [Abstract][Full Text] [Related]
6. Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A).
Atkins MB; Jegede OA; Haas NB; Mcdermott DF; Bilen MA; Stein M; Sosman J; Alter R; Plimack ER; Ornstein MC; Hurwitz M; Peace DJ; Einstein D; Catalano PJ; Hammers H; Regan MM
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604810
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032).
Callahan M; Amin A; Kaye FJ; Morse MA; Taylor MH; Peltola KJ; Sharma P; O'Reilly EM; Meadows Shropshire S; O'Brien S; Tschaika M; Le DT
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38316517
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
Postow MA; Chesney J; Pavlick AC; Robert C; Grossmann K; McDermott D; Linette GP; Meyer N; Giguere JK; Agarwala SS; Shaheen M; Ernstoff MS; Minor D; Salama AK; Taylor M; Ott PA; Rollin LM; Horak C; Gagnier P; Wolchok JD; Hodi FS
N Engl J Med; 2015 May; 372(21):2006-17. PubMed ID: 25891304
[TBL] [Abstract][Full Text] [Related]
9. A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma.
McKay RR; Leucht K; Xie W; Jegede O; Braun DA; Atkins MB; Grimm MO; Choueiri TK
Oncologist; 2024 Apr; 29(4):324-331. PubMed ID: 37950901
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial.
Powles T; Burotto M; Escudier B; Apolo AB; Bourlon MT; Shah AY; Suárez C; Porta C; Barrios CH; Richardet M; Gurney H; Kessler ER; Tomita Y; Bedke J; George S; Scheffold C; Wang P; Fedorov V; Motzer RJ; Choueiri TK
ESMO Open; 2024 May; 9(5):102994. PubMed ID: 38642472
[TBL] [Abstract][Full Text] [Related]
11. First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial.
Cytryn SL; Moy RH; Cowzer D; Shah RH; Chou JF; Joshi SS; Ku GY; Maron SB; Desai A; Yang J; Sugarman R; Rao D; Goldberg Z; Charalambous C; Lapshina M; Antoine A; Socolow F; Trivedi N; Capanu M; Gerdes H; Schattner MA; Simmons M; Lacouture ME; Paroder V; Tang LH; Shia J; Ilson DH; Solit DB; Berger MF; Janjigian YY
Lancet Oncol; 2023 Oct; 24(10):1073-1082. PubMed ID: 37666264
[TBL] [Abstract][Full Text] [Related]
12. Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE).
McKay RR; McGregor BA; Xie W; Braun DA; Wei X; Kyriakopoulos CE; Zakharia Y; Maughan BL; Rose TL; Stadler WM; McDermott DF; Harshman LC; Choueiri TK
J Clin Oncol; 2020 Dec; 38(36):4240-4248. PubMed ID: 33108238
[TBL] [Abstract][Full Text] [Related]
13. Real-world outcomes of nivolumab plus ipilimumab combination therapy for advanced renal cell carcinoma in Japanese patients: data with a minimum of 3 years of follow-up.
Ishihara H; Yuki N; Ishiyama R; Ikeda T; Kobari Y; Fukuda H; Yoshida K; Shimmura H; Hashimoto Y; Iizuka J; Kondo T; Takagi T
Jpn J Clin Oncol; 2024 May; 54(5):577-583. PubMed ID: 38251783
[TBL] [Abstract][Full Text] [Related]
14. Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM).
Vasudev NS; Ainsworth G; Brown S; Pickering L; Waddell T; Fife K; Griffiths R; Sharma A; Katona E; Howard H; Velikova G; Maraveyas A; Brown J; Pezaro C; Tuthill M; Boleti E; Bahl A; Szabados B; Banks RE; Brown J; Venugopal B; Patel P; Jain A; Symeonides SN; Nathan P; Collinson FJ; Powles T
J Clin Oncol; 2024 Jan; 42(3):312-323. PubMed ID: 37931206
[TBL] [Abstract][Full Text] [Related]
15. Salvage ipilimumab associated with a significant response in sarcomatoid renal cell carcinoma.
George G; Schmidt L; Tolat P; Riese M; Kilari D
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114501
[TBL] [Abstract][Full Text] [Related]
16. CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma.
Albiges L; Schmidinger M; Taguieva-Pioger N; Perol D; Grünwald V; Guemas E
Future Oncol; 2022 Mar; 18(8):915-926. PubMed ID: 34911359
[TBL] [Abstract][Full Text] [Related]
17. First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.
Imai H; Kijima T; Azuma K; Kishi K; Saito H; Yamaguchi T; Tanizaki J; Yoneshima Y; Fujita K; Watanabe S; Kitazono S; Fukuhara T; Hataji O; Toi Y; Mizutani H; Hamakawa Y; Maemondo M; Ohsugi T; Suzuki K; Horinouchi H; Ohe Y
Jpn J Clin Oncol; 2024 Apr; 54(4):452-462. PubMed ID: 38271158
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass).
Grünwald V; Ivanyi P; Zschäbitz S; Wirth M; Staib P; Schostak M; Dargatz P; Müller L; Metz M; Bergmann L; Steiner T; Welslau M; Lorch A; Rafiyan R; Hellmis E; Darr C; Schütt P; Meiler J; Kretz T; Loidl W; Flörcken A; Mänz M; Hinke A; Hartmann A; Grüllich C
Eur Urol; 2023 Dec; 84(6):571-578. PubMed ID: 37758574
[TBL] [Abstract][Full Text] [Related]
19. Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis.
Knisely A; Hinchcliff E; Fellman B; Mosley A; Lito K; Hull S; Westin SN; Sood AK; Schmeler KM; Taylor JS; Huang SY; Sheth RA; Lu KH; Jazaeri AA
Med; 2024 Apr; 5(4):311-320.e3. PubMed ID: 38471508
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
Motzer RJ; Escudier B; McDermott DF; George S; Hammers HJ; Srinivas S; Tykodi SS; Sosman JA; Procopio G; Plimack ER; Castellano D; Choueiri TK; Gurney H; Donskov F; Bono P; Wagstaff J; Gauler TC; Ueda T; Tomita Y; Schutz FA; Kollmannsberger C; Larkin J; Ravaud A; Simon JS; Xu LA; Waxman IM; Sharma P;
N Engl J Med; 2015 Nov; 373(19):1803-13. PubMed ID: 26406148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]